Results 61 to 70 of about 14,484 (178)
ANALYSIS OF THE COST OF THE DISEASE — PROBLEMS AND SOLUTIONS
Педиатрическая фармакология, 2011 The article discusses the estimation of the disease value, which includes direct, indirect and «intangible» costs. Advantages and disadvantages of different approaches to cost accounting, including the method of direct costs microcalculation compared ...
V.V. Omel'yanovskii +3 more
doaj +2 more sources
ClinicoEconomics and Outcomes ResearchWenjuan Wang,1,* Dachuang Zhou,1,* Kejia Zhou,1 Di Zhang,1 Hao Li,1 Hongliu Zhang,1 Xin Jiang,1 Ruihua Wang,1 Xi Wang,2 Wenxi Tang1 1Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu ...
Wang W +9 more
doaj
Navigating Healthcare Economics Optimizing Therapeutic Efficacy and Cost with Pharmacoeconomics
Journal of Pharmacoeconomics and Pharmaceutical ManagementBackground: In today's healthcare landscape, escalating costs underscore the pressing need for pharmacoeconomic evaluations, particularly in low- and middle-income countries (LMICs) where medication expenses can dominate healthcare budgets ...
Rania Indu, Moumita Ray, Sudipto Mangal
doaj
Pharmacoeconomics of HIV-infection
Регуляторные исследования и экспертиза лекарственных средств, 2018 Ever since the first registrations of HIV-infections at the territory of the Russian Federation there was started a great process on arrangement and, subsequently, development of anti-HIV system.
R. I. Yagudina +3 more
doaj
Development and validation of the Chinese patient-centered integrated care scale
BMC Health Services ResearchBackground The healthcare system is currently facing challenges in transitioning to a more integrated, patient-centered care. China has implemented various practical exploration and pilot programs in developing an integrated healthcare service system ...
Yue Yin +3 more
doaj +1 more source
PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE
Кардиоваскулярная терапия и профилактика, 2015 Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic
Yu. M. Lopatin, E. Yu. Lopatina
doaj +1 more source
PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS
Рациональная фармакотерапия в кардиологии, 2018 Aim. To perform pharmacoeconomic analysis of CHF therapy with supramolecular sacubitril/valsartan complex compared to routine therapy in patients with diabetes type 2 and ACE inhibitor intolerance within context of Russian healthcare system.Material and ...
S. K. Zyryanov +2 more
doaj +1 more source
Multidisciplinary Respiratory Medicine, 2018 After publication of the Original research article [1] it was brought to our attention that the sentence at pag 6 (between Figure 3 and Figure 4)) must be corrected as follows: “The mean duration of inactivity was 2.88 (0.63) at baseline; 1.53 (0.27 ...
Roberto W. Dal Negro +2 more
doaj +1 more source
A Claims-Based Algorithm for Identifying Hidradenitis Suppurativa Severity
Clinical EpidemiologyMaria C Schneeweiss,1– 3 Priyanka Anand,1,2 Arash Mostaghimi,2,3 Joan Landon,1,2 Denys Shay,1,4 Olivia MT Davies,2,3 Anusha Mohan Kumar,2,3 Aijing Shang,5 Tanja Tran,6 Robert J Glynn,1,2 Kueiyu Joshua Lin,1,2,7,8 Richard Wyss1,2 1Division of ...
Schneeweiss MC +11 more
doaj